Carrick Therapeutics

Market position

Carrick describes itself as a clinical-stage oncology biopharmaceutical company; its founder stated in 2018 an aim of becoming Europe's leading biotech oncology company. Cancer Research Horizons characterised samuraciclib's clinical development as a class-leading approach to a novel drug target. The sources do not provide market share, revenue or comparative ranking data.

Carrick positions its portfolio as first-in-class and best-in-class, centred on selective targeting of cyclin-dependent kinases—an emerging drug class—rather than on established oncology targets. Samuraciclib is described as an oral, first-in-class CDK7 inhibitor and CT7439 as a first-in-class CDK12/13 inhibitor / Cyclin-K glue-degrader. The company also cites biomarker-driven patient selection, a leadership team with prior drug development and commercialization experience, and a collaborative network spanning Imperial College London, the Royal College of Surgeons Dublin, Dana-Farber Cancer Institute and the University of Pennsylvania.

Technology

Two lead programs target cyclin-dependent kinases: samuraciclib (CT-7001, originally ICEC0942), an oral first-in-class CDK7 inhibitor, and a CDK12/13 inhibitor / Cyclin-K glue-degrader (CT7439). CDKs regulate transcription, metabolism and cell differentiation; CDK7 in particular regulates transcription of cancer-causing genes, drives uncontrolled cell-cycle progression and contributes to resistance to anti-hormone therapy. Programs are advanced with technologies to identify therapeutics and stratify the patients most likely to benefit, including biomarker-driven patient selection.

Go-to-market

Development is pursued through partnerships at each stage: licensing assets from originators such as Cancer Research Horizons, running trials with contract research organizations and academic clinicians, and entering combination clinical trial collaborations with large pharmaceutical companies including Pfizer, Roche and Arvinas. Business development inquiries for in-licensing are directed to the Chief Business Officer.

Patients with aggressive and treatment-resistant solid tumors, principally hormone receptor-positive, HER2-negative advanced breast cancer (including CDK4/6-inhibitor-resistant disease), triple-negative breast cancer, androgen-resistant prostate cancer and ovarian cancer, with further potential stated in pancreatic cancer and Ewing's sarcoma. Commercially, the company also engages pharmaceutical partners and asset originators for licensing and combination trials.

Geography

Corporate headquarters at One Marina Park Drive, Suite 1410, Boston, Massachusetts 02210, USA, established in June 2024, plus a Dublin office at Regus Dublin Blanchardstown, Block 1, Blanchardstown Corporate Park, Ballycoolin Road, Dublin 15. Earlier coverage (2018) described teams in Dublin and Oxford, and 2022 press releases were datelined Dublin, Ireland and Boston. Academic and clinical collaborators span the UK, Ireland and the US.

History

Sources describe the company as founded/launched in 2016 with $95 million in Series A/B funding from a syndicate of healthcare investors, with teams in Dublin and Oxford. Its lead asset ICEC0942 was discovered by a Cancer Research UK-funded multidisciplinary team at Imperial College London in collaboration with Emory University, and licensed to Carrick from Cancer Research Horizons; it is now known as samuraciclib (CT-7001). In November 2017 Carrick announced the first patient dosed in the Phase 1 programme of CT7001, less than two years after taking on the preclinical candidate. Initial Phase 1 combination data with fulvestrant were presented at ESMO in 2021, followed by a clinical collaboration with Roche on samuraciclib plus giredestrant. In December 2022 Carrick closed a $25 million Series C from existing investors and disclosed a separate $35 million investment and development collaboration with Pfizer. Subsequent milestones include a July 2023 clinical trial collaboration with Arvinas and Pfizer, FDA clearance of the CT7439 IND in September 2023, multiple first-patient-dosed announcements in 2023-2024, the establishment of a Boston headquarters in June 2024, and positive Phase 2 randomized data for samuraciclib plus fulvestrant announced in December 2025.

Risks & controversies

The sources do not report controversies. Inherent risks evident from the material include dependence on a small number of clinical-stage assets (samuraciclib and CT7439), reliance on partner-supplied combination agents and development capabilities, and the absence of any approved product or disclosed revenue.